Please wait while the formulary information is being retrieved.
VARUBI (rolapitant HCl)
- Prevention of chemotherapy-induced nausea and vomiting
90 mg tablet
- 2 tablets (180 mg) by oral route once within 2 hours prior to the initiation of chemotherapy
166.5 mg/92.5 mL intravenous emulsion
- Infuse 92.5 milliliters (166.5 mg) over 30 minute(s) by intravenous route once within 2 hours prior to the initiation of chemotherapy
Prevention of chemotherapy-induced nausea and vomiting
- Infuse 92.5 milliliters (166.5 mg) over 30 minute(s) by intravenous route once within 2 hours prior to the initiation of chemotherapy
- 2 tablets (180 mg) by oral route once within 2 hours prior to the initiation of chemotherapy
- None
Contraindicated
- B cplx-C-St.Johnwrt-K.&S.ginsg
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cerebyx
- Cold & Flu Fighter
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- enzalutamide
- Epitol
- Equetro
- Fatigue Relief Complex
- fosphenytoin
- isoniazid-rifamp-pyrazinamide
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- Soltamox
- St. John's wort
- tamoxifen
- Tegretol
- Tegretol Xr
- vit C-St. John wort-elder-hb30
- Women's Complex
- Xtandi
Severe
Moderate
- Conzip
- Synapryn
- tramadol
- tramadol-acetaminophen
- tramadol-glucosamine
- Ultracet
- Ultram
- Ultram Er
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
VARUBI (rolapitant HCl)
- Prevention of chemotherapy-induced nausea and vomiting
- Neutropenic disorder
- Anorexia
- Dizziness
- Hiccups
More Frequent
Severe
Less Severe
- Anemia
- Acute abdominal pain
- Dyspepsia
- Paresthesia
- Sensation of warmth
- Stomatitis
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Dyspnea
- Hypersensitivity drug reaction
Less Severe
- Hypotension
- Urticaria
- Wheezing
Contraindicated
None
Severe Precaution
Rolapitant
Possible developmental disorders. No safety and efficacy established.
- 1 Day – 18 Years
- Possible developmental disorders. No safety and efficacy established.
Management or Monitoring Precaution
None
Rolapitant
- Severity Level:
2
- Additional Notes: Insufficient human data available; animal data do not suggest dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Rolapitant
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool